Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TOI vs AMS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TOI Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

TOI Overall Winner 6-Pillar Tally: TOI 3 – 3 AMS Matrix Metrics: TOI 5 – 5 AMS

As of Nov 16, 2026, The Oncology Institute, Inc. (TOI) is the stronger overall head-to-head candidate over American Shared Hospital Services (AMS) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). TOI carries a Unified Composite Score of 53.5/100 (HOLD) at $5.13 (N/M Forward P/E, -4.4% operating margin), whereas AMS carries 33.8/100 (SELL) at $1.07 (44.6x Forward P/E, -7.4% operating margin).

  • Technical & Structure Timing Caution: TOI trades in a Neutral technical trend (SURGE options phase, RSI 48.6); meanwhile AMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TOI vs AMS
TOI NASDAQ Head-to-Head Winner
The Oncology Institute, Inc. Common Stock
Services-Offices & Clinics Of Doctors Of Medicine
$5.13
+5.56% 1D
Market Cap $506.9M
TTM Revenue $546M
Forward P/E N/M
Beta / 30D Vol 1.66β · 73% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.6 · SMA20: $5.41 · SMA50: $5.16
AMS NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap $7.2M
TTM Revenue $30M
Forward P/E 44.6x
Beta / 30D Vol 0.18β · 46% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 24.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 27
RSI-14: 27.1 · SMA20: $1.21 · SMA50: $1.32

6-Pillar Scorecard Institutional Category Breakdown (TOI 3 – 3 AMS)

Columns: Metric · TOI · AMS
1. Valuation Multiples AMS
Forward P/E N/M 44.6x
Trailing P/E N/M 44.6x
PEG Ratio N/M N/M
EV / Revenue 1.0x 0.8x
2. Growth & Scale TOI
Revenue Growth (YoY) +41.2% +19.2%
Earnings Growth (YoY) +0.0% -38.1%
TTM Revenue (USD) $546M $30M
Market Cap $506.9M $7.2M
3. Profitability & Quality AMS
Gross Margin 15.1% 34.8%
Operating Margin -4.4% -7.4%
Net Profit Margin -8.0% -5.8%
Return on Equity (ROE) -651.7% -12.1%
4. Balance Sheet & Cash Flow TOI
Cash Generation (TTM) -$3.3M -$916,000
Cash Flow Margin -0.6% -3.0%
Net Cash / Leverage $63M Net Debt $17M Net Debt (0.95x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TOI
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 80.2% (35th %ile) N/A (N/A)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AMS
OpEx & R&D Intensity 19.5% of Rev ($106M) 42.2% of Rev ($13M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TOI (5) vs AMS (5)
Institutional Metric TOI AMS Criterion Row Edge
Market Capitalization
Scale
$506.9M $7.2M Larger Scale TOI
Trailing P/E Ratio
Valuation
N/M 44.6x Lower Multiple AMS
Forward P/E Ratio
Valuation
N/M 44.6x Lower Multiple AMS
Revenue Growth (YoY)
Growth
+41.2% +19.2% Higher Growth TOI
Operating Margin (TTM)
Profitability
-4.4% -7.4% Higher Margin TOI
Net Profit Margin
Profitability
-8.0% -5.8% Higher Margin AMS
Return on Equity (ROE)
Capital Efficiency
-651.7% -12.1% Higher ROE AMS
52-Week Range Position
Momentum
65% ($2–$7) 6% ($1–$2) Stronger Trend TOI
Beta / 30D Volatility
Risk Regime
1.66β · 73% Vol 0.18β · 46% Vol Lower Realized Risk AMS
Unified Institutional Score
Composite Signal
53.5 / 100 (HOLD) 33.8 / 100 (SELL) Higher Composite TOI
Trailing 12M Revenue (USD)
Operating Scale
$546M $30M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
15.1% 34.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.0x EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.3M ($63M Net Debt) -$916,000 ($17M Net Debt (0.95x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AMS +2.5 pp
TOI: -2.84% · AMS: -0.34%
3M Horizon TOI +39.32 pp
TOI: +26.67% · AMS: -12.65%
6M Horizon TOI +119.25 pp
TOI: +89.3% · AMS: -29.95%
1Y Horizon TOI +100.27 pp
TOI: +66.56% · AMS: -33.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period TOI Revenue AMS Revenue TOI Op. Margin AMS Op. Margin Margin Leader
FY2018 N/A $20M N/A 9.4% AMS
FY2019 N/A $20M N/A 7.5% AMS
FY2020 $190M $20M -4.4% -53.1% TOI
FY2021 $200M $20M -22.6% 7.7% AMS
FY2022 $250M $20M -32.5% 12.3% AMS
FY2023 $320M $20M -23.8% 1.3% AMS
FY2024 $390M $30M -15.3% -9.9% AMS
FY2025 $500M $30M -7.2% -12.8% TOI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TOI SURGE
14d in phase · OBV DISTRIBUTION
Current IV 80.2%
IV Percentile 35th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TOI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AMS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TOI Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $506.9M market capitalization and -4.4% operating margin.
OpEx & R&D Reinvestment 19.5% of Rev ($106M)
90D Engineering Disclosures 0 Published
AMS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $7.2M market capitalization and -7.4% operating margin.
OpEx & R&D Reinvestment 42.2% of Rev ($13M)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (18 partners):
Taiwan Semiconductor Manufacturing Company GlobalFoundries ASE Technology Holding Amkor Technology

Investor FAQ TOI vs AMS Key Questions & Quantitative Answers

As of Nov 16, 2026, The Oncology Institute, Inc. (TOI) is the stronger overall head-to-head candidate over American Shared Hospital Services (AMS) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). TOI carries a Unified Composite Score of 53.5/100 (HOLD) at $5.13 (N/M Forward P/E, -4.4% operating margin), whereas AMS carries 33.8/100 (SELL) at $1.07 (44.6x Forward P/E, -7.4% operating margin). Technical & Structure Timing Caution: TOI trades in a Neutral technical trend (SURGE options phase, RSI 48.6); meanwhile AMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TOI leads the Growth & Scale pillar: TOI posts +41.2% YoY revenue growth and +0.0% YoY earnings growth on $546M TTM revenue (15.1% gross margin, -4.4% operating margin), compared with AMS at +19.2% YoY revenue growth and -38.1% YoY earnings growth on $30M TTM revenue (34.8% gross margin, -7.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), TOI cumulative revenue shifted +163.2% while AMS shifted +50.0%. In operating R&D and SG&A reinvestment, TOI deploys 19.5% of Rev ($106M) (0 90-day corporate R&D disclosures) versus 42.2% of Rev ($13M) (0 disclosures) for AMS.

AMS screens cheaper on headline valuation multiples. TOI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.0x EV/Revenue (-0.6% FCF margin), whereas AMS trades at 44.6x Forward P/E, 44.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TOI (-651.7% ROE) versus AMS (-12.1% ROE) capital efficiency.

In options market volatility and institutional positioning, TOI carries 80.2% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (1.66β · 73% Vol realized risk). By comparison, AMS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.